Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLTE Belite Bio	$60.92 -0.1%	$61.79	$43.70 ▼ $86.53	$1.94B	-1.5	47,457 shs	30,551 shs
CNTA Centessa Pharmaceuticals	$15.69 -1.7%	$13.24	$9.00 ▼ $19.09	$2.13B	1.45	773,725 shs	1.01 million shs
OPT Opthea	$3.41 +7.2%	$3.41	$2.02 ▼ $6.30	$524.84M	1.17	27,381 shs	3,000 shs
VCEL Vericel	$35.34 -2.5%	$41.54	$35.19 ▼ $63.00	$1.83B	1.32	427,175 shs	545,056 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLTE Belite Bio	-1.71%	-1.68%	+4.17%	+8.14%	+26.64%
CNTA Centessa Pharmaceuticals	+1.98%	+8.94%	+26.67%	+29.76%	+67.65%
OPT Opthea	0.00%	0.00%	0.00%	0.00%	+64.73%
VCEL Vericel	-2.32%	-12.05%	-12.63%	-12.05%	-29.89%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BLTE Belite Bio	1.83 of 5 stars	3.5	2.0	1.3	0.8	0.6
CNTA Centessa Pharmaceuticals	3.4103 of 5 stars	3.5	4.0	2.3	3.3	0.6
OPT Opthea	0.391 of 5 stars	1.1	0.0	2.7	0.8	0.6
VCEL Vericel	3.6805 of 5 stars	3.5	5.0	3.3	0.0	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLTE Belite Bio	3.00	Buy	$96.67	58.68% Upside
CNTA Centessa Pharmaceuticals	3.00	Buy	$27.89	77.75% Upside
OPT Opthea	2.17	Hold	$1.33	-60.90% Downside
VCEL Vericel	3.00	Buy	$61.14	73.01% Upside

Current Analyst Ratings Breakdown

Latest OPT, BLTE, CNTA, and VCEL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/3/2025	BLTE Belite Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$100.00
6/16/2025	VCEL Vericel	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$67.00
5/28/2025	CNTA Centessa Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$35.00
5/22/2025	VCEL Vericel	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$67.00 ➝ $67.00
5/15/2025	BLTE Belite Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
5/15/2025	BLTE Belite Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$100.00 ➝ $100.00
5/8/2025	CNTA Centessa Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform ➝ Outperform	$6.00
5/8/2025	CNTA Centessa Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLTE Belite Bio	N/A	N/A	N/A	N/A	$4.72 per share	N/A
CNTA Centessa Pharmaceuticals	$6.85M	305.90	N/A	N/A	$3.05 per share	5.14
OPT Opthea	$120K	4,373.61	N/A	N/A	($0.56) per share	-6.09
VCEL Vericel	$237.22M	7.50	$0.30 per share	116.04	$5.92 per share	5.97

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLTE Belite Bio	-$36.14M	-$1.36	N/A	N/A	N/A	N/A	-32.07%	-30.91%	8/8/2025 (Estimated)
CNTA Centessa Pharmaceuticals	-$235.76M	-$1.81	N/A	N/A	N/A	N/A	-40.22%	-29.95%	8/12/2025 (Estimated)
OPT Opthea	-$220.24M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/29/2025 (Estimated)
VCEL Vericel	$10.36M	$0.03	1,178.39	80.32	N/A	1.25%	1.09%	0.73%	7/31/2025 (Estimated)

Latest OPT, BLTE, CNTA, and VCEL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	CNTA Centessa Pharmaceuticals	-$0.34	N/A	N/A	N/A	N/A	N/A
8/8/2025	Q2 2025	BLTE Belite Bio	-$0.42	N/A	N/A	N/A	N/A	N/A
7/31/2025	Q2 2025	VCEL Vericel	-$0.04	N/A	N/A	N/A	$64.61 million	N/A
5/12/2025	Q1 2025	CNTA Centessa Pharmaceuticals	-$0.35	-$0.20	+$0.15	-$0.20	N/A	N/A
5/8/2025	Q1 2025	VCEL Vericel	-$0.09	-$0.23	-$0.14	-$0.23	$53.86 million	$52.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLTE Belite Bio	N/A	N/A	N/A	N/A	N/A
CNTA Centessa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
OPT Opthea	N/A	N/A	N/A	N/A	N/A
VCEL Vericel	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLTE Belite Bio	N/A	24.31	24.31
CNTA Centessa Pharmaceuticals	0.28	14.37	14.37
OPT Opthea	N/A	1.57	N/A
VCEL Vericel	N/A	5.01	4.58

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLTE Belite Bio	0.53%
CNTA Centessa Pharmaceuticals	82.01%
OPT Opthea	55.95%
VCEL Vericel	N/A

Insider Ownership

Company	Insider Ownership
BLTE Belite Bio	13.29%
CNTA Centessa Pharmaceuticals	7.09%
OPT Opthea	3.20%
VCEL Vericel	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLTE Belite Bio	10	31.84 million	27.61 million	Not Optionable
CNTA Centessa Pharmaceuticals	200	133.55 million	124.09 million	Optionable
OPT Opthea	8	153.91 million	148.99 million	Not Optionable
VCEL Vericel	300	50.34 million	47.73 million	Optionable

OPT, BLTE, CNTA, and VCEL Headlines

Recent News About These Companies

Vericel to Report Second-Quarter 2025 Financial Results on July 31, 2025

July 17 at 8:30 AM | globenewswire.com

Vericel Corporation (NASDAQ:VCEL) Shares Bought by Kornitzer Capital Management Inc. KS

July 17 at 6:29 AM | marketbeat.com

Vericel (NASDAQ:VCEL) Reaches New 52-Week Low - Should You Sell?

July 16 at 7:04 AM | marketbeat.com

Vericel (NASDAQ:VCEL) Shares Down 4.8% - What's Next?

July 15 at 2:10 PM | marketbeat.com

New York State Common Retirement Fund Increases Position in Vericel Corporation (NASDAQ:VCEL)

July 15 at 5:16 AM | marketbeat.com

TimesSquare Capital Management LLC Increases Stake in Vericel Corporation (NASDAQ:VCEL)

July 14, 2025 | marketbeat.com

Principal Financial Group Inc. Buys 7,222 Shares of Vericel Corporation (NASDAQ:VCEL)

July 14, 2025 | marketbeat.com

Allspring Global Investments Holdings LLC Sells 11,632 Shares of Vericel Corporation (NASDAQ:VCEL)

July 4, 2025 | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Receives Consensus Rating of "Buy" from Brokerages

July 2, 2025 | marketbeat.com

Lisanti Capital Growth LLC Acquires 13,585 Shares of Vericel Corporation (NASDAQ:VCEL)

June 29, 2025 | marketbeat.com

If EPS Growth Is Important To You, Vericel (NASDAQ:VCEL) Presents An Opportunity

June 20, 2025 | finance.yahoo.com

Vericel Corporation: Moving From Sell To Neutral

June 12, 2025 | seekingalpha.com

Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025

June 11, 2025 | morningstar.comM

Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025

June 10, 2025 | globenewswire.com

5VCEL : What Analysts Are Saying About Vericel Stock

May 23, 2025 | benzinga.com

Vericel at BofA Securities Conference: Growth and Innovation in Healthcare

May 16, 2025 | investing.com

Which Is a Better Investment, BioCryst Pharmaceuticals, Inc. or Vericel Corporation Stock?

May 10, 2025 | aaii.comA

Vericel Corporation: Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance

May 9, 2025 | finanznachrichten.de

Vericel Corp (VCEL) Q1 2025 Earnings Call Highlights: Record Revenue and Strategic Growth ...

May 9, 2025 | finance.yahoo.com

Vericel Corporation 2025 Q1 - Results - Earnings Call Presentation

May 8, 2025 | seekingalpha.com

Vericel Corporation (VCEL) Q1 2025 Earnings Conference Call Transcript

May 8, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters
By Gabriel Osorio-Mazilli | July 15, 2025
View Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters
Palantir Gets Price Hike From Wedbush Amid High Valuation
By Chris Markoch | July 15, 2025
View Palantir Gets Price Hike From Wedbush Amid High Valuation
Chipotle: Too Spicy for Smart Money to Resist After Stock Split
By Jeffrey Neal Johnson | July 11, 2025
View Chipotle: Too Spicy for Smart Money to Resist After Stock Split
Reddit Stock Ignites: Surge in Call Options Signals Big Bet
By Gabriel Osorio-Mazilli | June 24, 2025
View Reddit Stock Ignites: Surge in Call Options Signals Big Bet
Salesforce Stock Set for 30% Upside to Reach New Highs
By Thomas Hughes | July 16, 2025
View Salesforce Stock Set for 30% Upside to Reach New Highs

OPT, BLTE, CNTA, and VCEL Company Descriptions

Belite Bio NASDAQ:BLTE

$60.92 -0.07 (-0.11%)

Closing price 04:00 PM Eastern

Extended Trading

$61.20 +0.27 (+0.45%)

As of 04:04 PM Eastern

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Centessa Pharmaceuticals NASDAQ:CNTA

$15.69 -0.27 (-1.69%)

Closing price 04:00 PM Eastern

Extended Trading

$16.10 +0.41 (+2.61%)

As of 07:23 PM Eastern

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Opthea NASDAQ:OPT

$3.41 +0.23 (+7.23%)

As of 07/17/2025

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Vericel NASDAQ:VCEL

$35.34 -0.92 (-2.54%)

Closing price 04:00 PM Eastern

Extended Trading

$36.68 +1.34 (+3.79%)

As of 06:10 PM Eastern

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time